Company / R&D Expense
Corvus Pharmaceuticals, Inc. R&D Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$19.4M
FY2024
5-year range
$16.5M / $31.8M
FY2020-FY2024
Trend
+17.3%
vs FY2023
Sector context
#197 of 209
Health Care
What the data says
Among 209 Health Care companies, Corvus Pharmaceuticals, Inc. is in the bottom 6% for r&d expense. R&D Expense returned to growth in FY2024 after 6 years of decline, reaching $19M.
Based on SEC 10-K filings.
$19M in FY2024 with a 5-year CAGR of -12.6%.
Declined from $24M to $19M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -12.7%
- 5-Year CAGR
- -12.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 209This company $19.4M Sector average $647.6M
▼
-97.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -12.6%, indicating a declining trend.
- In FY2024, r&d expense increased 17.3% year-over-year.
- Ranks #197 out of 209 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $19.4M | +17.3% |
| FY2023 | $16.5M | -32.5% |
| FY2022 | $24.5M | -16.0% |
| FY2021 | $29.1M | -8.5% |
| FY2020 | $31.8M | -16.2% |
| FY2019 | $38.0M | -1.6% |
| FY2018 | $38.6M | -16.7% |
| FY2017 | $46.3M | +57.7% |
| FY2016 | $29.4M | +158.6% |
| FY2015 | $11.4M | +29773.7% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026